公开(公告)号：EP1724262A4

公开(公告)日：2009-10-21

申请号：EP05709816

申请日：2005-02-07

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： HATTORI KAZUO ,  NIIZUMA SATOSHI ,  OKADA TAKEHIRO ,  EDA HIROYUKI ,  TATSUNO KENJI ,  YOSHIDA MIYUKI

IPC分类号： C07D217/24 ,  A61K31/472 ,  A61K31/496 ,  A61K31/5377 ,  A61P35/00 ,  A61P43/00 ,  C07D401/04

CPC分类号： C07D217/24

公开(公告)号：EP2050749A4

公开(公告)日：2011-03-30

申请号：EP07792065

申请日：2007-08-07

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： SHIMMA NOBUO ,  EBIIKE HIROSATO ,  OHWADA JUN ,  KAWADA HATSUO ,  MORIKAMI KENJI ,  NAKAMURA MITSUAKI ,  YOSHIDA MIYUKI ,  ISHII NOBUYA ,  HASEGAWA MASAMI ,  YAMAMOTO SHUN ,  KOYAMA KOHEI

IPC分类号： C07D487/04 ,  A61K31/5377 ,  A61P35/00

CPC分类号： C07D487/04

摘要： A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R 1 represents a cyclic substituent].